AbbVie Inc. (4AB.DE)
169.92
-3.36 (-1.94%)
At close: Jan 14, 2025, 5:25 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 300.27B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.81 |
| PE Ratio (ttm) | 60.47 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 385 |
| Avg. Volume (20D) | 2,399 |
| Open | 173.92 |
| Previous Close | 173.28 |
| Day's Range | 169.46 - 174.06 |
| 52-Week Range | 141.98 - 192.50 |
| Beta | undefined |
About 4AB.DE
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date May 17, 2016
Employees 50,000
Stock Exchange XETRA
Ticker Symbol 4AB.DE
Website https://www.abbvie.com